88 results
424B5
ATHE
Alterity Therapeutics Ltd
15 Feb 24
Prospectus supplement for primary offering
5:28pm
capability would materially impair our ability to successfully market and sell our pharmaceutical products.
If healthcare insurers and other … subsidiaries may develop and market may be later withdrawn from the market or subject to promotional limitations.
Healthcare reform measures and other
F-3
ATHE
Alterity Therapeutics Ltd
2 Oct 23
Shelf registration (foreign)
8:44am
would materially impair our ability to successfully market and sell our pharmaceutical products.
If healthcare insurers and other organisations do … may develop and market may be later withdrawn from the market or subject to promotional limitations.
Healthcare reform measures and other statutory
6-K
EX-99.1
ATHE
Alterity Therapeutics Ltd
31 Aug 23
Report of Foreign Private Issuer
12:58pm
ability to successfully market and sell our pharmaceutical products.
If healthcare insurers and other organisations do not pay for our products … be later withdrawn from the market or subject to promotional limitations.
Healthcare reform measures and other statutory or regulatory changes could
6-K
EX-99.1
ATHE
Alterity Therapeutics Ltd
31 Aug 23
Report of Foreign Private Issuer
10:11am
as Company
Medicine / Healthcare / Research
– other
MBA
AICD Member, Graduate or Fellow
Directorships (current and previous)
Gender
Industry – same
6-K
EX-99.1
wqeycd3
31 Aug 22
Report of Foreign Private Issuer
2:08pm
6-K
EX-99.1
t8aq7pn
31 Aug 22
Report of Foreign Private Issuer
11:54am
6-K
EX-99.1
t34758pe82scw
22 Jul 22
Appendix 4C – Q4 FY22 Quarterly Cash Flow Report
6:02am
6-K
EX-99.1
yffkbn cf4
14 Jun 22
Alterity Therapeutics to Present at the GCFF Virtual Conference 2022 – Investing in Healthcare
6:02am
6-K
EX-99.1
ifnr33225wr4
26 May 22
Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference
6:05am
6-K
EX-99.1
ypa8n 7wg55k5l42469
2 May 22
Appendix 4C – Q3 FY22 Quarterly Cash Flow Report
6:35am
6-K
EX-99.1
ouo6d4l8vu dx01tozey
27 Apr 22
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom
6:04am
6-K
EX-99.1
zhuq2d27bfgynjriu3f0
27 Jan 22
Appendix 4C – Q2 FY22 Quarterly Cash Flow
6:06am
6-K
EX-99.1
azwya1dojm7
3 Sep 21
Report of Foreign Private Issuer
6:15am
6-K
EX-99.1
ycqu656ls
29 Apr 21
Appendix 4C – Q3 FY21 Quarterly Cash Flow Report
6:04am
6-K
EX-99.1
wjjcff u1wgst8
10 Mar 21
Alterity CEO Dr David Stamler presents to US investors at Authorization & Additional information
6:19am
6-K
EX-99.1
foo497 txx71pn
11 Jan 21
Alterity participates in world’s largest virtual healthcare conference JP Morgan
6:25am
6-K
2qgv 1yyk
11 Jan 21
Alterity participates in world’s largest virtual healthcare conference JP Morgan
6:25am